Latest news with #SGFinserve
Yahoo
12-05-2025
- Business
- Yahoo
SG Finserve Ltd (BOM:539199) Q4 2025 Earnings Call Highlights: Strong AUM Growth Amidst ...
Release Date: May 09, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. SG Finserve Ltd (BOM:539199) achieved a 48% quarter-on-quarter increase in AUM, showcasing strong growth momentum. The company has expanded its anchor list to over 45 major conglomerates, including JSW, Adani, Bajaj, Tata, and Vedanta. SG Finserve Ltd (BOM:539199) maintained a healthy spread of 4% with an average yield of 12.5% and stable borrowing costs at 8.5%. The company has a clear growth trajectory with plans to increase its loan book to 4,000 crores in FY26 and 6,000 crores by FY27. SG Finserve Ltd (BOM:539199) has strengthened its funding ecosystem with 14 banks and sanction limits of about 1,500 crores. The company's total income for FY25 was slightly lower than the previous year due to a contraction in the loan book during the first half. Profit before tax remained flat compared to the previous quarter, despite significant growth in AUM. There are concerns about the company's ability to generate returns for shareholders, as highlighted by investor questions. The company faced regulatory challenges in the first half of FY25, impacting its financial performance. SG Finserve Ltd (BOM:539199) relies heavily on bank financing, which may pose risks if market conditions change. Warning! GuruFocus has detected 4 Warning Signs with BOM:539199. Q: What are the top three foreseeable and unforeseeable risks that could impact SG Finserve's business over the next 12 to 14 months, and what internal controls are in place to mitigate these risks? A: Monitoring cash flows daily is crucial. We are launching an AI-based monitoring tool to extract data from the GST portal monthly, tracking sales and purchases. This will help ensure borrowers use funds correctly and repay on time. External factors like macroeconomic changes could impact liquidity, but our short 35-day cycle helps absorb such impacts. Q: Can you explain the breakdown of fee income and other income? A: Fee income consists of processing fees. Other income includes a provision that was made in the first nine months and has been written back as it was not required. Q: What disbursement numbers are you aiming for over the next few quarters? A: We added about 750 crores per quarter in Q3 and Q4 FY25. We aim for a loan book of 4,000 crores in FY26, adding about 1,600 crores. We expect gross disbursements to increase to 3,000-3,500 crores monthly as the loan book grows. Q: Why is the profit flat compared to the last quarter despite a 50% growth in AUM? A: In Q3, we had low-cost debt from the group, which supported profits. In Q4, all debt was market debt, which affected profitability. The previous support from the promoter was not available in Q4, so the performance reflects market standards. Q: What is the long-term goal of the company for the next five years? Will SG Finserve remain in supply chain financing, or expand into other areas? A: We see a massive opportunity in supply chain funding, especially with the current gaps in financial institutions. We plan to expand downstream to distributors and retailers, leveraging data collection to enhance offerings. We aim to maintain an ROE threshold of 18% while exploring growth opportunities within the supply chain segment. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Standard
09-05-2025
- Business
- Business Standard
SG Finserve standalone net profit declines 0.04% in the March 2025 quarter
Sales decline 7.57% to Rs 54.12 croreNet profit of SG Finserve declined 0.04% to Rs 23.79 crore in the quarter ended March 2025 as against Rs 23.80 crore during the previous quarter ended March 2024. Sales declined 7.57% to Rs 54.12 crore in the quarter ended March 2025 as against Rs 58.55 crore during the previous quarter ended March the full year,net profit rose 3.07% to Rs 80.99 crore in the year ended March 2025 as against Rs 78.58 crore during the previous year ended March 2024. Sales declined 9.85% to Rs 171.04 crore in the year ended March 2025 as against Rs 189.72 crore during the previous year ended March EndedYear EndedMar. 2025Mar. 2024% 2025Mar. 2024% -8 171.04189.72 -10 OPM %87.2788.49 -83.4089.16 - PBDT31.2231.99 -2 110.67105.19 5 PBT31.0831.91 -3 110.16105.02 5 NP23.7923.80 0 80.9978.58 3 Powered by Capital Market - Live News
Time of India
26-04-2025
- Business
- Time of India
Madhusudan Kela bites this crunchy pick in Mar quarter, adds 2 more smallcaps to his Rs 3,500 cr portfolio
Ace investor Madhusudan Kela added three new smallcap stocks in his portfolio in the quarter ended March 31, 2025 viz. Windsor Machines , SG Finserve and Prataap Snacks while raising stakes in Kopran . Kela, who has a portfolio worth over Rs 3,500 crore according to data available on Trendlyne, holds 17 stocks as per the latest shareholding data compiled by it. Windsor Machines The injection moulding machine manufacturer has a market capitalisation of Rs 2,388 crore on the BSE . Kela bought 7.71% stake in the company. The stock is down 17% in 2025 so far but has had a stellar journey over the past one year, delivering multibagger returns of 248%. SG Finserve SG Finserve is a tech-enabled non-banking finance company (NBFC). The stock has fallen over 1% this year while declining 7% on the 1-year basis. He bought a 1.70% stake in the company. Live Events Prataap Snacks Kela bought 4.61% stake in the Prataap Snacks counter. The market capitalisation on the BSE stands at Rs 2,918.41 crore. Shares of Prataap Snacks have risen 8% so far this year while rallying 35% over a 1 year period. Kopran Kela increased his holding by 42 bps in Kopran, bringing his stake to 1.46% in the March ended quarter from 1.04% at the end of the December quarter. Kopran is an integrated pharmaceutical company based out of Mumbai. The company is a manufacturer and supplier of formulations and Active Pharmaceutical Ingredients (API), worldwide. Kopran's manufacturing facilities and products have accreditations in all the continents, the company website claims. The stock has been on a losing side falling by 11% and 25% on a year-to-date and one-year basis. Kela also has stakes in other stocks like Nazara Technologies , Samhi Hotels , Rashi Peripherals , Unicommerce eSolutions and Waaree Energies . Also Read: Dolly Khanna portfolio: Ace investor adds 2 new smallcaps in March quarter, raises stake in Som Distilleries, 6 others ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
